Abstract: The present invention relates to novel bisphosphonate duplex drugs, methods for preparing said compound; pharmaceutical compositions containing the same; as well as the use of said compounds in human and veterinary medicine, and, in particular, for treating tumors, viral infections; or dental disorders.

Abstract: The present invention relates to novel bisphosphonate duplex drugs, methods for preparing said compound; pharmaceutical compositions containing the same; as well as the use of said compounds in human and veterinary medicine, and, in particular, for treating tumors, viral infections; or dental disorders.

Abstract: The invention relates to novel ethynylated heterodinucleoside phosphate analogs, the production thereof, substances containing at least one of said compounds, and the use thereof for the treatment of cancer and infectious diseases.

Abstract: The invention relates to a method for treating infectious diseases which are elicited by viruses which are pathogenic to humans comprising the step of administering an amphiphilic nucleoside-phosphonoformic acid derivative having an esterified or unesterified carboxyl group, preferably of a nucleoside-glycerol-(hydroxycarbonyl)-phosphonate, as an active compound.

Abstract: A method for treating viral diseases which are caused by DNA viruses is described comprising administering an effective amount of at least one inhibitor of reverse transcriptase (RTI) in combination with at least one inhibitor of viral DNA polymerase, wherein the at least one RTI and the at least one DNA polymerase inhibitor are present in the form of separate compounds.

Abstract: The invention relates to a method for treating infectious diseases which are elicited by viruses which are pathogenic to humans comprising the step of administering an amphiphilic nucleoside-phosphonoformic acid derivative having an esterified or unesterified carboxyl group, preferably of a nucleoside-glycerol-(hydroxycarbonyl)-phosphonate, as an active compound.

Abstract: The invention relates to glyceryl nucleotides of the formula Ia in which a) one of the radicals A1, A2 and A3 is a hydrogen atom or a radical selected from hydroxyl, mercapto, alkyl, alkenyl, polyoxyalkenyl, aryl, acyl, alkyloxy, alkenyloxy, polyoxyalkenyloxy, acyloxy, aryloxy, alkylthio, alkenylthio, acylthio and arylthio, where the alkyl, alkenyl and acyl radicals are optionally substituted by from 1 to 3 aryl radicals; and b1) two of the remaining radicals A1, A2 and A3 are two nucleoside groups which are different from each other; or b2) one of the remaining radicals A1, A2 and A3 is a nucleoside group and the other of the remaining radicals is a hydroxycarbonyl group, where at least one of the nucleoside groups is not a naturally occurring nucleoside group; to processes for preparing these compounds, to pharmaceutical remedies which comprise these compounds, and to the use of these compounds for treating cancer diseases and infectious diseases.

Abstract: A ballast weight arrangement for a working vehicle has an interlocking connection between a ballast weight and a ballast weight support in the transverse plane of the vehicle, wherein interlocking is brought about by at least one projection on the ballast weight engaging in a recess on an adjacent ballast weight. Interlocking is achieved by controlled movement of a locking member on lifting up ballast weight 8 from a deposit block 22 and be released on putting down ballast weight 8 on deposit block 22.

Abstract: A ballast weight arrangement for a working vehicle has an interlocking connection between a ballast weight and a ballast weight support in the transverse plane of the vehicle, wherein interlocking is brought about by at least one projection on the ballast weight engaging in a recess on an adjacent ballast weight. Interlocking is achieved by controlled movement of a locking member on lifting up ballast weight 8 from a deposit block 22 and be released on putting down ballast weight 8 on deposit block 22.

Abstract: Amphiphilic nucleoside phosphate analogues of formula I ##STR1## wherein R.sup.1 denotes a hydroxyl or amino group or an acylated or alkylated or polyoxyethylene-substituted amino group, the acyl or alkyl group of which is straight-chained or branched, has 1 to 24 carbon atoms and up to 2 double bonds and may be substituted by an aromatic group;R.sup.2 denotes H, F, a 2-bromo vinyl group or a straight-chained or branched C.sub.1-24 -alkyl group;R.sup.3 and R.sup.4 are identical or different and denote H, hydroxyl, halogen and azido; R.sup.5 denotes a nucleoside group of formula II ##STR2## wherein R.sup.6 denotes a hydroxyl or amino group or an acylated or alkalized amino group, the acyl or alkyl group of which is straight-chained or branched, contains 1 to 24 carbon atoms and up to 2 double bonds and may be substituted by an aromatic group, whilstR.sup.6 and R.sup.1 are different and one of the groups denotes acylamino or alkylamino groups having 12 to 24 carbon atoms,R.sup.1, R.sup.2, R.sup.6 and R.sup.

Abstract: Novel cytarabine derivatives of the formula ##STR1## where R.sup.1, R.sup.2 and R.sup.3, which can be identical or different, are each selected from the group consisting of hydrogen, aliphatic C.sub.2 -C.sub.5 -acyl, benzoyl or carboxy-C.sub.1 -C.sub.3 -alkylcarbonyl are described. The compounds are suitable for use directly or in the form of immunoliposomes for controlling diseases. Methods of preparing the novel cytarabine derivatives are also disclosed.